Loading clinical trials...
Loading clinical trials...
Prospective Observational Database Evaluating Outcomes of Using Carbetocin (Duratocin®) as the Primary Uterotonic Following Cesarean Delivery at Maisonneuve-Rosemont Hospital
Conditions
Interventions
Carbetocin
Locations
1
Canada
Maisonneuve-Rosemont hospital
Montreal, Quebec, Canada
Start Date
March 29, 2017
Primary Completion Date
March 16, 2018
Completion Date
March 16, 2018
Last Updated
May 29, 2019
NCT05380531
NCT05224726
NCT07130747
NCT06284421
NCT05791630
NCT04307069
Lead Sponsor
Maisonneuve-Rosemont Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions